Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons

Amani Elshaer,

David M. Chascsa, Blanca Lizaola‐Mayo

et al.

Life, Journal Year: 2024, Volume and Issue: 14(7), P. 844 - 844

Published: July 3, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading increased patient various complications. Recent research has been focused on new therapeutic strategies reduce the incidence and provide effective treatment plans prevent further irreversible damage. approach is multifactorial, primary focus weight loss management comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing exploring pharmacological therapies that could enhance MASLD.

Language: Английский

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications DOI Open Access
Giovanni Targher, Christopher D. Byrne, Herbert Tilg

et al.

Gut, Journal Year: 2024, Volume and Issue: unknown, P. gutjnl - 330595

Published: Jan. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic globally and is currently estimated to affect up 38% of global adult population. NAFLD a multisystem where systemic insulin resistance related metabolic dysfunction play pathogenic role in development its relevant liver-related morbidities (cirrhosis, failure hepatocellular carcinoma) extrahepatic complications, such as cardiovascular (CVD), type 2 diabetes mellitus, kidney disease, certain types cancers. In 2023, three large multinational associations proposed that dysfunction-associated steatotic (MASLD) should replace term NAFLD; name chosen non-alcoholic steatohepatitis was (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between MASLD definitions—that is, ~99% individuals with meet criteria. this narrative review, we provide overview literature on (a) recent data risk developing CVD malignant (b) underlying mechanisms by which (and factors strongly linked MASLD) may increase these complications (c) diagnosis assessment potential treatments reduce people or MASH.

Language: Английский

Citations

242
Steatotic liver disease DOI
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10464), P. 1761 - 1778

Published: Nov. 1, 2024

Language: Английский

Citations

28
Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence DOI
Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(8), P. 1762 - 1767

Published: April 10, 2024

A recent Delphi consensus proposed a new definition for metabolic dysfunction associated steatotic liver disease (MASLD) and introduced entity called MetALD, condition in which (SLD), moderate alcohol intake coexist. Given the limited available data on prognostic implications of these entities, we performed systematic review meta-analysis cohort studies to evaluate association MASLD MetALD with hard clinical outcomes. We included 5 total 9 824 047 participants. Compared participants without SLD, increased rates all-cause mortality incident cardiovascular were present both MetALD. Moreover, was also significantly higher risks cancer-related (n = 2 studies, random-effects HR 2.10, 95% CI 1.35-3.28) 3 1.17, 1.12-1.22). Although preliminary, evidence indicates more unfavourable prognosis patients compared those MASLD.

Language: Английский

Citations

16
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study DOI Open Access
Takao Miwa, Satoko Tajirika, Nanako Imamura

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(4), P. 1158 - 1158

Published: Feb. 19, 2024

This cross-sectional study examined the prevalence and characteristics of steatotic liver disease (SLD) based on a recently introduced nomenclature in Japanese health checkup population. SLD was evaluated using ultrasonography, participants were categorized into metabolic dysfunction-associated (MASLD), dysfunction alcohol associated (MetALD), alcohol-associated/related (ALD), cryptogenic groups. The subclasses assessed, subgroup analyses conducted for non-obese (body mass index [BMI] ≤ 25 kg/m2) lean (BMI 23 populations. Among 694 participants, with median age 47 years comprising 54% males, MASLD, MetALD, ALD, 26%, 2%, 1%, respectively. A remarkable difference observed according to age, sex, BMI. Subgroup revealed heterogeneous demographic, clinical, biochemical parameters between categories. Individuals MetALD had higher gamma-glutamyl transferase levels, lower platelet counts, fibrosis-4 than did those MASLD. Furthermore, MASLD 13% 6%, provides preliminary information new

Language: Английский

Citations

13
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review DOI Creative Commons

Haixiang Zheng,

Leonardo A. Sechi, Eliano Pio Navarese

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 28, 2024

Language: Английский

Citations

12
Systemic metabolic abnormalities: Key drivers of complications and mortality in MASLD DOI Open Access
Xiude Fan,

Bofei Zhang,

Yingzhou Shi

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 80(6), P. e246 - e248

Published: Feb. 2, 2024

Language: Английский

Citations

11
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis DOI Creative Commons

Renuka Suvarna,

Sahana Shetty, Joseph M Pappachan

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Aug. 26, 2024

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public health problem owing to its high prevalence and associated morbidity mortality secondary progressive cardiovascular events. Resmetirom, a selective thyroid hormone receptor-β agonist has been developed as therapeutic modality for MASLD. This systematic review meta-analysis aimed evaluate the effectiveness safety of resmetirom compared placebo in treatment Eligible studies were systematically identified by screening PubMed, Scopus, Web Science, Cochrane library, Embase, ClinicalTrials.gov from 2014 2024. Only randomized controlled trials comparing efficacy MASLD against included analysis. Meta-analysis was performed using RevMan 5.4 software. Four with low risk bias involving total 2359 participants identified. The metanalysis only three clinical 2234 participants. A significant reduction MRI-proton density fat fraction (MRI-PDFF) 80 mg Resmetirom that [SMD − 27.74 (95% CI 32.05 32.42), p < 0.00001] at 36–52 weeks well 12–16 30.92 36.44 25.40), 0.00001]. With 100 dose 36.05 40.67 31.43), 36.89 40.73 33.05), observed. LDL-c triglyceride, lipoproteins. enzymes. There FT4 increase SHBG sex steroids placebo. no major difference overall emergent adverse events [OR 1.55 0.84 2.87), 1.13 0.78 1.63), doses However, gastrointestinal diarrhoea nausea occurred ≥ 10% group 12 week. showed modest treating MRI-PDFF, LDL-c, lipoproteins, enzymes NASH biomarkers without concerns. Larger long-term RCTs may further confirm this promising outcomes use

Language: Английский

Citations

11
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia DOI Creative Commons
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(3), P. 577 - 579

Published: March 6, 2024

Language: Английский

Citations

10
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice DOI
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba

et al.

Seminars in Liver Disease, Journal Year: 2024, Volume and Issue: 44(01), P. 035 - 042

Published: Feb. 1, 2024

In June 2023, under the patronage of American Association for Study Liver Disease, European Liver, and Asociación Latinoamericana para el Estudio del Hígado with involvement 236 participants from around world, a new nomenclature definition nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic (MASLD) was defined as presence hepatic steatosis at least one cardiometabolic risk factors alcohol intake less than 140 g/wk women 210 men no other causes steatosis. A entity called combined metabolic dysfunction- alcohol-associated (MetALD) created outside pure MASLD patients dysfunction greater that allowed (i.e., 140–350 210–420 men). Recent studies have confirmed 95% overlap between NAFLD diagnostic criteria. Natural history, biomarkers, thresholds in MetALD group remains to be studied validated.

Language: Английский

Citations

9
ZBP1-mediated apoptosis and inflammation exacerbate steatotic liver ischemia-reperfusion injury DOI Creative Commons
Yizhi Liu, Huan Cao, Shu‐Hua Zhang

et al.

Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 134(13)

Published: May 14, 2024

There is increasing need to expand availability of donor liver grafts, including steatotic livers. However, the current use grafts in transplantation less acceptable due their higher susceptibility ischemia-reperfusion (I/R) injury. To investigate mechanism underlying I/R injury, we detected cell death markers and inflammation clinical livers animal models. We found that caspase-8-mediated hepatic apoptosis activated I/R. ablation caspase-8 only slightly mitigated injury without affecting inflammation. further demonstrated RIPK1 kinase induces both death-independent Inhibition significantly protects against by alleviating Additionally, activation induced Z-DNA binding protein 1 (ZBP1) but not canonical TNFα pathway during Deletion ZBP1 substantially decreases Mechanistically, amplified palmitic acid-activated JNK Upon I/R, excessive reactive oxygen species trigger inducing its aggregation independent Z-nucleic acids sensing action livers, leading subsequent aggravation Thus, ZBP1-mediated RIPK1-driven exacerbate which could be targeted protect transplantation.

Language: Английский

Citations

9